The company is governed by a board of directors.
John Pierce – Chairman of the board:
Throughout his career, John Pierce has focused on the integration of biology with chemistry, engineering, and material sciences to create biotechnological applications in agricultural chemistry, plant genetics, and industrial biology. He received a PhD in 1980 from Michigan State University in the areas of carbohydrate chemistry and enzymology. Most recently, he was the Chief Bioscientist for BP plc after a long period with DuPont during which he led the development of a number of commercially successful biotechnological applications.
Marc Delcourt, CEO and Co-founder, Board member:
Global Bioenergies, Marc Delcourt is a former student of the Ecole Normale Supérieure, biology section. After completing a thesis in North America , it is towards R & D activities in the field of bioprocess and created in 1997 the first company in the field of industrial biology, Biométhodes. He left Biométhodes in 2008, then founded Global Bioenergies.
Philippe Marlière, Co-founder, Board member:
Philippe Marlière chairs the Scientific Council. Former student of the Ecole Normale Supérieure, he devoted his academic career to the launch of synthetic biology. He then continued his scientific activities based biotechnology companies.
Alain Fanet, Board member:
Alain Fanet has been an entrepreneur and executive for more than 20 years. He created two Franco-American companies in the high-tech sector: Arteris and T.sqware. He was recently Chairman and CEO of CXIgnited, an innovative company specialized in traceability of the supply channels in the luxury industry. Alain Fanet earned his PHD in Computer Science from ParisTech
Pierre Lévi – Permanent representative of METMAN CAPITAL, Board member:
Pierre Lévi performed management functions in significant international groups, such as Groupe Salins (CEO), Faurecia (Chairman and CEO) or Rhône-Poulenc/Rhodia (Deputy President). He advises several innovative companies through his holding Metman Capital. Pierre Lévi is a graduate from Ecole des Mines of Paris and Warton School (MBA).
Corinne Granger, Board member:
Corinne Granger, is Director of Research and Development, over 14 years in Cosmetics and Dermatology Industries and hold several R&D positions during more than 30 years in Health Care. She set up several R&D units around the world. She is Doctor in Medicine from Bordeaux University and hold a certificate on governance of enterprises from ESSEC business school Paris.
Muriel Atias – Permanent representative BOLD – BOLD Business Opportunities for L’Oréal Development, Observer:
Muriel Atias is the Chief Investment Officer of BOLD Business Opportunities for L’Oréal Development, L’Oréal’s corporate venture capital fund aiming to take minority stakes in innovative companies and brands with high growth potential. Having graduated from the ESSEC Business School, Muriel has over 17 years of experience in mergers and acquisitions, of which 10 in an investment bank. She joined L’Oréal in 2014, first in the Corporate Finance team in charge of acquisitions for the Group then at BOLD Business Opportunities for L’Oréal Development when launched in December 2018.